SGRQ total | EQ-5D VAS | UCSD-SOBQ | WHO-5 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
A) Multivariable model including QoL at last available follow-up | ||||||||||||
QoL at last available follow-up a | 1.12 | 1.06; 1.18 | < 0.001 | 0.91 | 0.87; 0.96 | 0.001 | 1.14 | 1.08; 1.20 | < 0.001 | 0.83 | 0.69; 0.99 | 0.048 |
Age a | 1.32 | 1.14; 1.54 | < 0.001 | 1.30 | 1.12; 1.51 | 0.001 | 1.27 | 1.09; 1.48 | 0.002 | 1.25 | 1.07; 1.46 | 0.006 |
Number of comorbidities | ||||||||||||
0 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
1 | 2.40 | 1.15; 5.01 | 0.02 | 1.93 | 0.98; 3.77 | 0.057 | 2.51 | 0.92; 6.81 | 0.071 | 2.03 | 0.93; 4.41 | 0.075 |
2 | 2.10 | 1.02; 4.32 | 0.043 | 1.62 | 0.83; 3.19 | 0.161 | 2.40 | 0.90; 6.40 | 0.079 | 2.24 | 1.05; 4.80 | 0.038 |
3 | 2.78 | 1.26; 6.09 | 0.011 | 2.15 | 1.02; 4.53 | 0.043 | 3.16 | 0.99; 10.05 | 0.052 | 2.31 | 0.97; 5.46 | 0.057 |
4+ | 1.95 | 0.69; 5.49 | 0.205 | 1.98 | 0.77; 5.07 | 0.155 | 1.30 | 0.29; 5.86 | 0.734 | 2.80 | 1.00; 7.86 | 0.051 |
Change in FVC % predicted | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 1.63 | 0.98; 2.71 | 0.058 | 1.60 | 0.97; 2.64 | 0.066 | 1.41 | 0.75; 2.64 | 0.286 | 1.75 | 1.01; 3.03 | 0.047 |
Decrease by > 10% | 2.34 | 1.18; 4.62 | 0.015 | 2.29 | 1.16; 4.51 | 0.017 | 2.14 | 0.87; 5.26 | 0.096 | 2.70 | 1.32; 5.53 | 0.007 |
Hospitalisation | 1.26 | 0.80; 1.97 | 0.322 | 1.54 | 0.98; 2.40 | 0.06 | 1.00 | 0.57; 1.74 | 0.994 | 1.29 | 0.81; 2.06 | 0.286 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Slow progression | 1.48 | 0.92; 2.38 | 0.106 | 1.70 | 1.08; 2.69 | 0.022 | 1.30 | 0.71; 2.37 | 0.399 | 1.91 | 1.16; 3.17 | 0.012 |
Rapid progression | 0.97 | 0.46; 2.04 | 0.933 | 1.18 | 0.55; 2.53 | 0.674 | 1.06 | 0.46; 2.42 | 0.896 | 1.25 | 0.53; 2.95 | 0.617 |
No judgement possible | 0.89 | 0.46; 1.74 | 0.743 | 0.98 | 0.52; 1.84 | 0.95 | 1.26 | 0.54; 2.93 | 0.588 | 0.94 | 0.47; 1.91 | 0.871 |
B) Multivariable model including change in QoL between baseline and last available follow-up | ||||||||||||
Change in QoL between baseline and last available follow-up a | 1.05 | 0.98; 1.13 | 0.148 | 0.97 | 0.91; 1.04 | 0.364 | 1.07 | 0.98; 1.16 | 0.127 | 0.85 | 0.68; 1.07 | 0.165 |
Age a | 1.30 | 1.11; 1.52 | 0.001 | 1.31 | 1.12; 1.53 | 0.001 | 1.26 | 1.02; 1.56 | 0.031 | 1.26 | 1.07; 1.48 | 0.006 |
Number of comorbidities | ||||||||||||
0 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
1 | 1.98 | 0.97; 4.04 | 0.061 | 1.83 | 0.92; 3.63 | 0.084 | 2.03 | 0.71; 5.84 | 0.187 | 1.93 | 0.89; 4.20 | 0.096 |
2 | 1.85 | 0.90; 3.79 | 0.092 | 1.70 | 0.85; 3.40 | 0.135 | 2.01 | 0.65; 6.21 | 0.226 | 2.14 | 0.99; 4.63 | 0.054 |
3 | 2.40 | 1.10; 5.24 | 0.028 | 2.25 | 1.06; 4.76 | 0.035 | 3.68 | 1.17; 11.55 | 0.026 | 2.18 | 0.91; 5.23 | 0.082 |
4+ | 2.04 | 0.75; 5.57 | 0.165 | 2.27 | 0.87; 5.92 | 0.093 | 1.54 | 0.26; 9.06 | 0.634 | 2.99 | 1.09; 8.22 | 0.034 |
Change in FVC % predicted | ||||||||||||
Stable/increase | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Decrease by 0 to 10% | 1.69 | 1.02; 2.82 | 0.044 | 1.65 | 0.99; 2.76 | 0.055 | 1.11 | 0.57; 2.14 | 0.762 | 1.67 | 0.95; 2.91 | 0.073 |
Decrease by > 10% | 2.16 | 1.08; 4.31 | 0.029 | 2.26 | 1.14; 4.50 | 0.02 | 1.72 | 0.71; 4.14 | 0.227 | 2.43 | 1.18; 5.00 | 0.015 |
Hospitalisation | 1.35 | 0.85; 2.13 | 0.202 | 1.54 | 0.98; 2.42 | 0.059 | 1.30 | 0.68; 2.45 | 0.427 | 1.30 | 0.81; 2.08 | 0.285 |
Overall physician’s judgement of clinical course of IPF | ||||||||||||
Stable disease | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Slow progression | 1.69 | 1.05; 2.73 | 0.03 | 1.83 | 1.14; 2.94 | 0.012 | 1.38 | 0.67; 2.85 | 0.381 | 1.89 | 1.15; 3.12 | 0.013 |
Rapid progression | 1.42 | 0.69; 2.91 | 0.341 | 1.63 | 0.76; 3.46 | 0.207 | 1.27 | 0.47; 3.41 | 0.636 | 1.38 | 0.61; 3.12 | 0.439 |
No judgement possible | 0.97 | 0.49; 1.92 | 0.922 | 0.96 | 0.50; 1.83 | 0.902 | 1.24 | 0.52; 2.95 | 0.622 | 0.83 | 0.39; 1.77 | 0.635 |